Antibodies to membranes of endothelial cells and fibroblasts in scleroderma

Clinical and Experimental Immunology

Volumn 106, Issue 3, 1996, Pages 491-497

  Hill, M B ^a,c   Phipps, J L ^a   Cartwright, R J ^a   Milford Ward, A ^a   Greaves, M ^b   Hughes, P ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Endothelial antibodies; Immunoblotting; Scleroderma

Indexed keywords

AUTOANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; SCLERODERMA; SYNDROME CREST; SYSTEMIC SCLEROSIS;

EID: 0029830369     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-867.x     Document Type: Article

References (39)

1. Tuffanelli DL, Winkelmann RK. Scleroderma and its relationship to the 'collagenoses' dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome. Am J Med Sci 1962; 243:133-46.
2. Catoggio LJ, Bernstein RM, Black CM et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42:23-27.
3. Fritzler MJ, Kinsella TD, Garbutt E. The CREST syndrome; a distinct serological entity with anticentromere antibodies. Am J Med 1980; 69:520-6.
4. Pisko E, Gallup K, Turner R et al. Cardiopulmonary manifestations of progressive systemic sclerosis. Association with circulating immune complexes and fluorescent antinuclear antibodies. Arthritis Rheum 1979; 22:518-23.
5. 1q binding, K cell inhibition and raji cell radioimmunoassays. J Clin Lab Immunol 1983; 10:133 8.
6. Roumm AD, Whiteside TL, Medsger TA Jr et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtypes and clinical correlations. Arthritis Rheum 1984; 27:645 53.
7. Kahaleh MB, Le Roy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989; 110:446-50.
8. Umehara H, Kumagai S, Murakami M et al. Enhanced productions of interleukin-1 and tumour necrosis factor α by cultured peripheral blood monocytes from patients with scleroderma. Arthritis Rheum 1990; 33:893-7.
9. Stasny P, Stambridge VA, Ziff M. Homologous disease in the adult rat, a model for autoimmune disease. I General features and cutaneous lesions. J Exp Med 1963; 118:635-48.
10. Furst DE, Clements PJ, Graze P et al. A syndrome resembling progressive systemic sclerosis after bone marrow transplantation; a model for scleroderma? Arthritis Rheum 1979; 22:904-10.
11. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970; 73:317-24.
12. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54:880-9.
13. Rosenbaum J, Pottinger BE, Woo P et al. Measurement and characterization of anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988; 72:450-6.
14. Penning CA, Cunningham J, French MAH et al. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 1984; 57:548-56.
15. Marks RM, Czerniecki M, Andrews BS et al. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 1988; 31:1524-34.
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
17. Lindsey NJ, Dawson RA, Henderson FI et al. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br J Rheumatol 1993; 32:123-6.
18. van der Zee JM, Siegert CGH, De Veede TH et al. Characterisation of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol 1991; 84:234-44.
19. Cui YC, Tai PC, Gatter KC. A vascular endothelial antigen with restricted distribution in human fetal, adult and malignant tissues. Immunology 1983; 49:183-9.
20. Harper DR, Liu KM, Kangro HO. Protein blotting ten years on. J Virol Methods 1990; 30:26-40.
21. Johnson GD, Dorling J. Immunofluorescence and immunoperoxidase techniques. In: Thompson RA, ed. Techniques in clinical immunology, 2nd edn. Oxford: Blackwell, 1981:106-37.
22. Powell FC, Winkelman RK, Venencie-Lemarchand F et al. The centromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27:125-31.
23. Lee M, White PAE, Milford-Ward A. Evaluation of the SIGMA SIA anti-ds-DNA test kit. MDD Evaluation Report, MDD/94/43. London: DH Medical Devices Directorate, 1994:27.
24. Feltkamp TEW, Kirkwood TPL, Maini RN et al. The First International Standard for antibodies to double stranded DNA. Ann Rheum Dis 1988; 47:740-6.
25. Milford-Ward A. Immunoprecipitation in the evaluation of the proteins in plasma and body fluids. In: Thompson RA, ed. Techniques in clinical immunology, 2nd edn. Oxford: Blackwell, 1981:1-27.
26. Chan TM, Frampton G, Cameron J. Identification of DNA binding proteins on human umbilical vein endothelial cell plasma membrane. Clin Exp Immunol 1993; 91:110-4.
27. Guldner HH, Szostecki C, Vosberg HP et al. Sci 70 autoantibodies from scleroderma patients recognise a 95 kDa protein identified as DNA topoisomerase I. Chromosoma 1986; 94:132-8.
28. Guldner HH, Lakomek HJ, Bautz FA. Anti-(UI)RNP and anti-Sm autoantibody profiles in patients with systemic rheumatic diseases: differential detection of immunoglobulin G and M by immunoblotting. Clin Immunol Immunopathol 1986; 40:532-8.
29. Wolin SL, Steitz JA. The Ro small cytoplasmic nibonucleoproteins: identification of the antigenic protein and its binding site to the Ro RNAs. Proc Natl Acad Sci USA 1984; 81:1996-2000.
30. Earnshaw W, Bordwell B, Marino C, Rothfield N. Three human chromosomal autoantigens are recognised by sera from patients with centromere antibodies. J Clin Invest 1986; 77:426-30.
31. Greaves M, Malia RG, Milford Ward A et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 1988; 27:281-5.
32. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic actions. Arthritis Rheum 1991; 34:978-83.
33. Kallenberg CG, Vellenga G, Wouda AA et al. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982; 9:878-84.
34. Kahaleh MB, LeRoy EC. Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 1983; 101:553-60.
35. Blake DR, Winyard P, Scott DGI et al. Endothelial cell cytotoxicity in inflammatory vascular diseases - the possible role of oxidised lipoproteins. Ann Rheum Dis 1985; 44:176-82.
36. Penning CA, Wright JK, Ashby JC et al. Serum-induced enhancement of peripheral blood mononuclear cell-mediated cytotoxicity towards human target cells in systemic sclerosis. J Clin Lab Immunol 1983; 12:77-81.
37. Chan TM, Frampton G, Staines NA et al. Different mechanisms by which anti-DNA MoAbs bind to human endothelial cells and glomerular mesangial cells. Clin Exp Immunol 1992; 88:68-74.
38. Le Feber WP, Norris DA, Ryan SR et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 1984; 74:1545-51.
39. Lindsey NJ, Henderson FI, Malia R et al. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1994; 33:20-26.